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Abstract In the majority of congenital disorders of glycosyl-
ation, the assembly of the glycan precursor GlcNAc2-
Man9Glc3 on the polyprenol carrier dolichyl-pyrophosphate
is compromised. Because N-linked glycosylation is essential
to life, most types of congenital disorders of glycosylation
represent partial losses of enzymatic activity. Consequently,
increased availability of substrates along the glycosylation
pathway can be beneficial to increase product formation by
the compromised enzymes. Recently, we showed that in-
creased dolichol availability and improved N-linked glycosyl-
ation can be achieved by inhibition of squalene biosynthesis.
This review summarizes the current knowledge on the bio-
synthesis of dolichol-linked glycans with respect to deficien-
cies in N-linked glycosylation. Additionally, perspectives on
therapeutic treatments targeting dolichol and dolichol-linked
glycan biosynthesis are examined.
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Dolichol biosynthesis and its role in N-linked
glycosylation
N-linked glycosylation occurs in all domains of life and the
same basic molecular principles underlie this type of post-
translational modification [1, 2]. Briefly, an oligosaccharide
precursor is assembled on a lipid carrier before the oligosaccha-
ride is transferred to a target protein. In eukaryotes, N-linked
protein glycosylation requires the assembly of the oligosaccha-
ride precursor at both the outer and inner leaflet of the ER
membrane [3]. The precursor is first assembled on dolichyl-
pyrophosphate (Dol-PP) starting at the cytoplasmic side. The
intermediate Dol-PP-GlcNAc2Man5 is then flipped to the lumi-
nal side of the ER where the assembly proceeds to Dol-PP-
GlcNAc2Man9Glc3. Noteworthily, dolichol (Dol) serves as lipid
carrier in eukaryotes and archaea whereas another isoprenoid
alcohol, bactoprenol, is used in bacteria. Apart from its role as
carrier of the oligosaccharide GlcNAc2Man9Glc3, Dol is used to
form the activated monosaccharides Dol-P-Man and Dol-P-Glc,
which are substrates for glycosyltransferases involved in N-
glycosylation, O-mannosylation, C-mannosylation and glyco-
sylphosphatidylinositol (GPI) anchor biosynthesis.
Dol biosynthesis begins at the mevalonate pathway (Fig. 1)
[4, 5], which produces essential isoprenoids. Isoprenoids are
divided into two classes: sterol isoprenoids, such as cholesterol
and steroid hormones, and non-sterol isoprenoids, encompass-
ing polyprenols, ubiquinone, and Dol. Starting from acetyl-
CoA via acetoacetyl-CoA, 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) is first produced. The reduction from HMG-
CoA to mevalonate is catalyzed by the rate-limiting HMG-
CoA reductase (HMGCR) enzyme. Mevalonate is then phos-
phorylated to mevalonate-P by mevalonate kinase (MVK). A
second phosphorylation step and subsequent decarboxylation
leads to isopentenyl-5-pyrophosphate (IPP), which represents
an important building block for isoprenoids. IPP is an activated
isoprene unit of five carbon atoms and is used to form farnesyl-
pyrophosphate. At this point, the pathway diverges to feed on
the one hand the biosynthesis of cholesterol and on the other
hand the biosynthesis of non-sterol isoprenoids. To obtain Dol,
dehydrodolichyl diphosphate synthase (DHDDS) catalyzes the
stepwise head-to-tail cis addition of IPP to farnesyl-
pyrophosphate, thus giving rise to polyprenyl-pyrophosphates
of 15 to 19 isoprene units. These polyprenyl-pyrophosphates
are then dephosphorylated by pyro- or monophosphatases. The
resulting polyprenols are reduced at the α1 position to become
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Dol of different lengths. Dol is then phosphorylated by Dol
kinase (DOLK). Dol-P can then be utilized as the carrier for the
oligosaccharide GlcNAc2Man9Glc3 or as a carrier for Man and
Glc. Dol-P-Man is produced by the Dol-P-Man synthase
(DPM1-3) that transfers Man from GDP-Man to Dol-P [6].
Similarly, Dol-P-Glc is produced by the glucosyltransferase
ALG5 that transfers Glc from UDP-Glc to Dol-P [7].
Importantly, Dol levels at the cytoplasmic leaflet of the ER
are not only maintained by de novo synthesis but also depend
on recycling of discharged Dol-PP and Dol-P. Once the oli-
gosaccharide precursor is transferred to a target protein, Dol-
PP is released and dephosphorylated to Dol-P by the luminal
phosphatase DOLPP1 [8]. Dol-P is then flipped across the
membrane to the cytoplasmic leaflet by a yet unknown mech-
anism [9]. Recycling of Dol-P and Dol-PP contributes signif-
icantly to the Dol pool available glycosylation in the ER.
Accordingly, a defect of the DOLPP1 orthologue in yeast
leads to impaired N-linked glycosylation [10].
Deficiency of dolichol biosynthesis—a new family
of CDG
Several forms of congenital disorders of glycosylation (CDG)
caused by Dol biosynthesis defects have been characterized
recently. The long sought polyprenol reductase has been iden-
tified though the description of SRD5A3-CDG [11] and
DHDDS deficiency was discovered in a subgroup of retinitis
pigmentosa patients [12].Moreover, the clinical picture of Dol
kinase deficiency was extended through the description of
new cases presenting with dilated cardiomyopathy [13].
Proximal to Dol, a defect along the mevalonate pathways
has also been linked to diseases. Mutations of MVK (Fig. 1)
cause of two different forms: mevalonic aciduria (MVA)
[14] and hyperimmunoglobulinemia D syndrome (HIDS)
[15]. In MVA, MVK activity is reduced to 0–4 % of normal
values leading to death in early childhood. Typcial symp-
toms (Table 1) are psychomotor retardation, failure to thrive,
progressive cerebellar ataxia, dysmorphic features, progres-
sive visual impairment and frequent febrile attacks [5, 16,
17]. Psychomotor retardation, failure to thrive, dysmorphic
features, and visual impairment are also frequently found in
CDG, thus suggesting possible glycosylation problems in
MVA. HIDS is a milder form of the disease correlating with
residual MVK activity of 5–15 % of normal values. In
HIDS, febrile attacks and skin rashes start in early childhood
and can be triggered by diverse events, such as vaccinations
or minor infections. The febrile disposition is believed to be
linked to insufficient levels of anti-inflammatory isopreny-
lated proteins. Low geranylgeranyl-PP in HIDS leads to
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Fig. 1 Dolichol and cholesterol
biosynthesis pathway. Two
acetyl building blocks are
required for HMG-CoA forma-
tion. HMG-CoA reductase
(HMGCR) catalyzes the rate
limiting step, the formation of
mevalonate. Mevalonate kinase
(MVK) phosphorylates meval-
onate in a CTP-dependent
manner. Sequential action of
dehydrodolichyl diphosphate
synthase (DHDDS), pyro- or
monophophatases, 5α steroid
reductase type 3 (SRD5A3),
and dolichol kinase (DOLK)
produce Dol-P. Dol-P-Man
synthase (DPM1-3) transfers a
mannose to Dol-P. Squalene
synthase (FDFT1) produces
squalene from farnesyl-PP and
subsequent action of squalene
epoxidase (SQLE), and 2,3-
oxidosqualene cyclase (OSC)
leads to lanosterol. Dotted
arrows indicate simplifications
of the biosynthetic pathway and
* point out known congenital
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caspase-1 activation and IL-1β secretion [18, 19]. Other
symptoms found in HIDS (Table 1) are mental retardation,
ataxia, ocular symptoms and epilepsy [17]. Diagnosing
HIDS involves the detection of increased mevalonic acid
in urine and increased serum immunoglobulin D and A.
Apart from febrile attacks, the clinical features of MVA
and HIDS are reminiscent of CDG. Indeed, metabolic label-
ling experiments with [14C]galactose in MVK deficient
fibroblasts revealed lower secretion of the radio-labelled
macromolecules indicating impaired glycosylation, which
is possibly due to decreased formation of Dol and Dol-P
[20]. However, systematic analysis of glycosylation in
HIDS has not been performed yet.
Recently, DHDDS deficiency (Fig. 1) has been linked to
inherited retinitis pigmentosa [12], a disorder causing retinal
degeneration with an estimated incidence of 1 in 3,000–
4,500. The single mutation identified was present in a very
small subgroup of retinitis pigmentosa patients [21]. Inter-
estingly, DHDDS patients did not show typical CDG symp-
toms despite the central role of DHDDS in Dol production
(Table 1). This fact suggests that DHDDS mutations associ-
ated with retinitis pigmentosa only partially impair
polyprenol-PP formation and that only few photoreceptor-
specific proteins may be sensitive to a reduced polyprenol-
PP pool. Note worthily, inhibition of N-linked glycosylation
by tunicamycin also leads to retinal degeneration in Xeno-
pus [22, 23]. Retinitis pimentosa is also associated with
MVK deficiency and with cases of phosphomannomutase
2 deficiency in PMM2-CDG [24].
The third disorder of Dol biosynthesis is a recently de-
scribed type of CDG, in which the SRD5A3 gene (Fig. 1) is
affected [25, 26]. SRD5A3 encodes the steroid 5α reductase
type 3 protein, which reduces the α-isoprene in polyprenol
to form Dol. Symptoms of SRD5A3-CDG are typical for
glycosylation disorders and encompass ocular malforma-
tions, cerebellar vermis hypoplasia, skin lesions, psychomo-
tor retardation, and facial dysmorphism (Table 1).
Strikingly, these multisystemic manifestations strongly dif-
fer from those found in DHDDS-CDG despite the proximity
of the two enzymes in the Dol pathway. Loss of whole N-
glycan chains on proteins has been described in SRD5A3-
CDG. Different mutations of SRD5A3 lead to truncated
forms of the protein resulting in loss of function. Residual
levels of Dol in SRD5A3 deficient cells suggest an alterna-
tive pathway for Dol biosynthesis.
Dol kinase deficiency, characterizing DOLK-CDG, impairs
the phosphorylation of Dol to Dol-P (Fig. 1). DOLK-CDG
presents with severe phenotypes including hypotonia, skin
disorders, and the loss of hair [27].Moreover, cardiomyopathy,
seizures, hypoglycemia, microcephaly, and visual impairment
can occur as well (Table 1). Due to the severity of the symp-
toms, most DOLK mutations generally cause a severe disease
associated with infant lethality. Reduced DOLK activity
decreases the availability of Dol-P and thus impairs the assem-
bly Dol-PP-GlcNAc2Man9Glc3 and N-linked glycosylation.
Recently, 11 children with dilated cardiomyopathy (DCM), a
disease possibly linked to sudden cardiac death and heart
failure, were found to have a novel mutation in DOLK [13].
Besides DCM, only few patients exhibit additional symptoms
like ichtyosis, failure to thrive, and mild neurological involve-
ment. Biochemical analysis of Dol-P dependent glycosylation
pathways of the DCM heart tissue indicated reduced O-
mannosylation of α-dystroglycan [28]. Remarkably, abnormal
N-glycosylation of serum transferrin was equally pronounced
Table 1 Disorders of dolichol
biosynthesis and their respective
symptoms
Symptoms are distinguished be-
tween ** for typical/dominant
symptoms and * for sporadic
symptoms or symptoms of
moderate severity
aClassical DOLK-CDG, bDOLK
defect in dilated cardiomyopathy
MVA HIDS DHDDS-
CDG
SRD5A3-
CDG
DOLK-
CDGa
DOLK-
CDGb
DPM1-
CDG
DPM3-
CDG
Cardiomyopathy * ** ** *
Cerebellar ataxia / malformation ** ** ** **
Coagulopathy ** **
Dysmorphic features ** ** **
Failure to thrive **
Febrile attacks ** **
Hypoglycemia **
Hypotonia ** **
Microcephaly ** * ** **
Muscular dystrophy ** *
Myopathy ** *
Ocular malfunctions ** ** ** ** **
Psychomotor retardation ** ** ** ** * **
Seizures ** * ** **
Skin disorders ** ** * ** *
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in all forms of DOLK-CDG. The phenotypes of DCM strongly
contrast with the originally described features of DOLK-CDG
[27], thus suggesting a possible tissue-specific regulation of
Dol-P dependent glycosylation.
Human Dol-P-Man synthase (DPM1-3, Fig. 1) consists of
3 subunits. DPM1 is the catalytic subunit and DPM2/3 are
regulatory and membrane anchoring proteins residing in the
ER membrane [6]. So far, two forms of Dol-P-Man synthase
deficiency have been associated with mutations in the DPM1
and DPM3 genes. DPM1-CDG is characterized by recurrent
seizures, hypotonia, developmental delay, dysmorphic fea-
tures, microcephaly, visual impairment, and in some cases
ataxia and coagulopathy (Table 1) [29–32]. Lower Dol-P-
Man levels lead to impaired Dol-PP-GlcNAc2Man9Glc3 as-
sembly, abnormal N-linked protein glycosylation, and de-
creased formation of GPI anchored proteins. DPM3-CDG
appears to be a milder form of Dol-P-Man synthase deficien-
cy, for which only one patient has been found so far [33]. The
symptoms included mild myopathy, a dilated cardiomyopa-
thy, moderate muscular dystrophy, and a single stroke-like
episode. N-glycosylation of serum transferrin was found to
be only slightly abnormal in DPM3-CDG. In DPM1-CDG
and DPM3-CDG, the severity seems to reflect the molecular
functions of the affected subunits. A deficiency of the catalytic
subunit DPM1 leads to much more severe phenotypes than a
deficieny in the tethering subunit DPM3.
In general, the clinical severity of Dol-related diseases
does not correlate with the relative position of the deficient
enzymes along the biosynthesis pathway. Defects of Dol
biosynthesis are severe since not only the assembly of N-
glycosylation is impaired, but also GPI anchor formation
and O-mannosylation are affected. This notion is confirmed
in SRD5A3-CDG that present with severe multisystemic
phenotypes. However, the discovery of DHDDS-CDG with
a very specific phenotype and lack of the typical CDG
symptoms suggests a complex regulation of Dol-dependent
glycosylation. Future efforts addressing Dol biosynthesis
will improve our comprehension of the regulation of N-
glycosylation and provide therapeutic perspectives.
Therapeutics targeting dolichol
To date, only two forms of CDG are treatable. MPI-CDG can
be successfully treated by oral mannose supplementation [34,
35]. In GFTP-CDG, deficient GDP-fucose transport can be
compensated by nutritional fucose supplementation [36]. The
hypomorphic nature of most CDG mutations allows for a
compensatory approach, for instance by providing more Dol
to overcome the compromised assembly of Dol-PP-
GlcNAc2Man9Glc3. Along this line, inhibition of squalene
synthase (FDFT1, Fig. 1) was shown to improve N-linked
protein glycosylation and GPI-anchored protein expression in
DPM1-CDG fibroblasts [37]. Additional drugs such as clofi-
brate were also tested as a way to increase GPI anchor avail-
ability in DPM1-CDG fibroblasts. Clofibrate decreases
cholesterol levels by targeting lipid metabolism via activation
of peroxisome proliferator-activated receptors, especially
PPARα [38, 39]. Indeed, surface expression of the GPI an-
chored protein CD59 was increased upon clofibrate treatment
(unpublished data). Similarly, the adenylate cyclase activator
forskolin [40] increased surface expression of CD59 as well.
This was in accordance with the notion that high levels of
cyclic AMP lead to higher activity of DHDDS and thus
increased Dol levels [41, 42].
New therapeutic possibilities arise for CDG with the
advance of non-statin cholesterol lowering drugs, which
target the late pathway of cholesterol biosynthesis. Present-
ly, statins are the prevalent medication to lower cholesterol
and decrease cardiovascular disease [43]. Statins are inhib-
itors of HMGCR (Fig. 1), the rate limiting enzyme at the
beginning of the mevalonate pathway. The effect of statins
on Dol levels has not been investigated systematically. Hela
cells treated with pravastatin showed a decrease in Dol-P by
65 % [44]. However, rats treated with lovastatin did not
show a change of total Dol-P levels but increase of Dol-P in
the liver [45]. The potential of different statins to upregulate
Dol could be subject of further investigations.
Inhibition of the first committed enzyme of cholesterol bio-
synthesis, squalene synthase (FDFT1, Fig. 1), has proven effec-
tive in lowering cholesterol production [46]. Prominent among
these inhibitors are zaragozic acids, which were identified in a
screen of fungal compounds for cholesterol lowering activity
[47]. Changes in Dol-P patterns were observed in human fibro-
blasts treated with zaragozic acid A. Also, DPM1-CDG fibro-
blasts showed improved N-linked glycosylation upon treatment
with zaragozic acid A [37]. Moreover, the expression of the
GPI-anchored CD59 protein could be normalized in DPM1-
CDG fibroblasts after treatment. Since zaragozic acid is well
tolerated in animals [48, 49], this class of FDFT1 inhibitors
might be considered for clinical testing in CDG.
Squalene epoxidase (SQLE) catalyzes the next commit-
ted step of cholesterol biosynthesis after FDFT1 (Fig. 1).
Inhibition of SQLE by the compound NB-598 ((E)N-ethyl-
N-(6,6-dimethyl-2-hepten-4-ynyl)-3-[(3,3′-bith iophen-5-yl)
methoxy]benzene-methanamine) successfully reduced cho-
lesterol levels [50, 51], although no changes in Dol levels
were detected in treated HepG2 cells [52]. In spite of this
early finding, newly developed SQLE inhibitors should be
considered as promising candidates for an upregulation of
Dol in CDG cells. Moreover, green tea has been attributed a
cholesterol lowering effect, which was linked to SQLE
inhibition [53]. In a recent study, oral supplementation with
the main green tea catechin epigallocatechin gallate was
shown to lower low density lipoprotein associated choles-
terol [54]. The effects of epigallocatechin gallate on Dol
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have not been tested yet. Catechins might represent another
family of compounds with the potential to upregulate Dol in
CDG cells by inhibition of SQLE.
In conclusion, inhibitors of late cholesterol biosynthesis
have a potential increasing effect on Dol levels and should
be accordingly tested in CDG cells. Much effort is invested
in the development of cholesterol lowering drugs in the
context of cardiovascular diseases. Therefore, potential
CDG therapies could profit from the discovery of novel
cholesterol lowering drugs in the future.
Outlook
The recent descriptions of tissue-restricted symptoms in
DHDDS-CDG and of a novel pathology associated to DOLK
deficiency suggest a pronounced tissue specificity of Dol-
related biology. Accordingly, additional diseases are likely to
be associated with local alterations of Dol biosynthesis in the
near future. The study of these tissue-restricted diseases rep-
resents valuable models to better understand the regulation of
Dol biosynthesis and its impact on various types of glycosyl-
ation. Novel therapeutic approaches may be deduced from
such insights. The treatment of CDG is still very limited and
merits further attention. Interference of cholesterol production
and thus upregulation of Dol biosynthesis certainly represents
a valuable approach to improve glycosylation in CDG.
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